New migraine prevention guidelines: treatment is recommended for as few as four migraine days per month.

For the first time since 2012, the American Academy of Neurology and the American Headache Society have completely updated their recommendations for migraine medication prophylaxis in adults. The new document was published on August 31, 2026, simultaneously in the journals Neurology and Headache and was endorsed by the American Academy of Family Physicians. The key change is that preventive treatment should now be considered for four or more migraine days per month, four or more days of moderate or severe headaches, or a reduction in attack frequency if attacks significantly interfere with work and daily life.

This is an important shift in the approach to migraine. Many people still perceive it as an episodic headache that should only be treated after an attack with painkillers or specific medications. The new guidelines emphasize that migraine is a chronic neurological disorder, for which, in some patients, it is advisable to address not only the individual attack but also reduce its likelihood in advance.

Another reason for the update is the dramatic shift in the therapeutic arsenal over the past 14 years. In 2012, the mainstay of prevention was medications originally developed for other conditions: beta-blockers, antiepileptic drugs, and some antidepressants. Since then, medications developed specifically around one of the key migraine mechanisms—the calcitonin gene-related peptide (CGRP) signaling system—have emerged. At least six such medications have received regulatory approval for migraine prevention since the previous guidelines were issued.

The authors do not declare one drug to be universally superior. They propose that the choice be made in consultation with the patient, taking into account evidence, side effects, comorbidities, cost, and ease of use. A person may prefer a daily pill, an every-other-day medication, a monthly subcutaneous injection, or a medication administered every three months. Essentially, the new strategy shifts migraine prevention from the "let's try a standard medication" approach to a much more individualized approach to therapy.

Key points of the 2026 recommendations

Position	What is recommended?
When to discuss prevention	≥4 migraine days per month
Alternative criterion	≥4 days of moderate/severe headache per month
Even at a lower frequency	If migraine significantly interferes with work or normal activities
Forms of migraine considered	Episodic and chronic
New drugs	Agents affecting the CGRP system
Old drugs	Remain important options
Choice of therapy	Joint decision between doctor and patient
What you need to consider	Efficacy, safety, concomitant diseases, cost, form of administration
First evaluation of the result	Usually in 8-12 weeks
Previous version of the recommendations	2012

Prevention is not the treatment of an attack that has already begun.

Medication for migraine is divided into two fundamentally different approaches. Acute therapy is used when an attack has already begun: its goal is to stop or quickly reduce headache, nausea, photophobia, and other symptoms. Preventative medications are taken regularly, regardless of pain—daily, every other day, monthly, or quarterly—to reduce the frequency of attacks and make them less severe.

Many patients underestimate the need for prevention. A person with six or eight attacks per month may successfully take pain medication each time and therefore consider the condition manageable. But if each attack takes several hours or an entire day, the overall loss of productivity and quality of life remains significant. New guidelines suggest assessing not only the number of headache days but also the actual functional impact of migraine on a person's life.

Therefore, the four-day threshold should not be understood as an absolute boundary between "treat" and "do not treat." If migraines occur three times a month, but each attack lasts two days and renders the person virtually unable to work, prophylaxis may still be justified. Conversely, the mere presence of four headaches does not automatically prescribe a specific medication: the doctor must confirm the diagnosis, evaluate the type of migraine, the medications already being used, and any contraindications.

This approach aligns well with recent international recommendations. The International Headache Society also recommends considering preventive treatment for headaches occurring on four or more days per month, significant impact on social or professional functioning, failure of optimal treatment, or excessive use of medications to relieve them.

When prevention is especially important

Clinical situation	Meaning
≥4 migraine days per month	Direct reason to suggest preventive treatment
≥4 days of moderate/severe headache	Also a basis for prevention
Less than 4 days, but severe disability	Prevention may be justified
Frequent use of medications for an attack	Reason to reconsider the treatment strategy
Attacks respond poorly to acute therapy	Increases the need for prevention
Significant side effects of seizure medications	Another argument in favor of a preventative approach
Significant loss of work/study time	Should be taken into account when choosing treatment

The new recommendations apply to both episodic and chronic migraine.

The previous 2012 guidelines focused primarily on episodic migraine. Since then, significantly more data has accumulated on the chronic form of the disease, so the updated document addresses both groups. This is especially important, as treatments effective for chronic migraine do not always have the same evidence base for infrequent attacks, and vice versa.

Chronic migraine is defined as a condition in which headaches occur at least 15 days a month for more than three months, with at least eight days having migraine-like features. Episodic migraine has fewer headache days. This boundary is important for clinical trials and the selection of certain medications, although in practice, patients may transition between these categories over time.

Chronicity significantly increases the burden of the disease. A person may be virtually constantly experiencing an attack, anticipating the next one, or recovering from a previous one. This increases the use of painkillers and other medications for pain relief, which in some patients further contributes to the development of headaches associated with medication overuse. Therefore, prevention for frequent migraines aims not only to reduce the number of attacks but also to break this cycle.

The emergence of medications proven effective for both episodic and chronic forms of headache has simplified the situation somewhat. This is particularly true for a number of CGRP-targeting agents. The American Headache Society previously noted that many of these are approved for both forms of the disease, which is convenient for patients whose headache frequency fluctuates over time.

Episodic and chronic migraine

Characteristic	Episodic	Chronic
Days of headaches	<15 per month	≥15 per month
The duration of this condition	-	>3 months
Days with signs of migraine	Depends on the frequency	≥8 per month
Is prevention necessary?	Often - with ≥4 days/month or significant influence	Very often
Risk of overuse of pain medications	Eat	Particularly relevant
Some specific methods	Many drugs	Including onabotulinumtoxinA and a number of CGRP drugs

The main revolution of recent years is anti-CGRP drugs.

Calcitonin gene-related peptide (CGRP) is involved in pain signaling in the trigeminal vascular system, which plays a key role in the pathophysiology of migraine. Studies have shown that CGRP can trigger migraine in susceptible individuals, and that blocking it reduces attack frequency. This has led to the development of the first widely used preventative medications specifically tailored to migraine mechanisms, rather than borrowing from cardiology, psychiatry, or epileptology.

There are two main types of such agents. Monoclonal antibodies either bind CGRP directly or block its receptor. This group includes erenumab, fremanezumab, galcanezumab, and eptinezumab. They are long-acting and used relatively rarely—usually subcutaneously every month or every few months, or, for some drugs, intravenously.

The second group consists of gepants, small molecules that block the CGRP receptor. These prophylactic medications include atogepant and rimegepant. Unlike antibodies, they are taken orally. In the 2026 guidelines, atogepant, eptinezumab, erenumab, fremanezumab, and galcanezumab received high ratings for efficacy and tolerability. For rimegepant, the authors assessed the evidence more cautiously and recommended its use for episodic migraine after alternatives with a stronger evidence base.

Interestingly, this differs somewhat from the 2024 position statement of the American Headache Society. At that time, the society concluded that sufficient evidence of the efficacy, safety, and tolerability of CGRP therapy had accumulated to consider these drugs first-line options, even without the necessary failure of several older preventive agents. This difference demonstrates that recommendations depend not only on regulatory approval but also on the evidence evaluation methodology of a specific expert group.

Modern drugs that act on CGRP

Preparation	Type	Main feature
Erenumab	Monoclonal antibody to the CGRP receptor	Migraine-specific prevention
Fremanezumab	Anti-CGRP antibody	Long-lasting action
Galcanezumab	Anti-CGRP antibody	Long-lasting action
Eptinezumab	Anti-CGRP antibody	Intravenous administration
Atogepant	Gepant	Oral prophylaxis
Rimegepant	Gepant	May be used for the prevention of episodic migraine; in guideline 2026 the evidence position is lower than some other options

Old drugs aren't going away: Topiramate, propranolol, and botulinum toxin remain important

One of the key messages of the new recommendation is that modern CGRP medications do not replace well-studied previous-generation treatments. For example, topiramate retains a substantial evidence base for migraine prevention. Propranolol remains an important option, primarily for episodic migraines, and onabotulinumtoxinA—botulinum toxin type A—has proven efficacy in chronic migraines.

Older medications have a significant advantage: decades of clinical experience. Their long-term side effects, interactions, and consequences for various patient groups are much better studied. Furthermore, many are available as inexpensive generic versions. This is especially important in areas where the cost of new biologics or insurance requirements limit access to CGRP therapy.

However, these medications were not originally developed for migraines. Topiramate is an antiepileptic drug; propranolol is a beta-blocker used in cardiology; and amitriptyline is a tricyclic antidepressant. Their prophylactic effect on migraines was discovered later. Therefore, choosing a medication can sometimes solve two problems at once: for example, choosing a drug that is potentially beneficial for a specific underlying condition. This is precisely the principle directly supported by the 2026 guidelines.

A comparison with the 2012 guidelines clearly demonstrates how much the field has changed. Back then, the medications with the most compelling evidence base included topiramate, divalproex/valproate, metoprolol, propranolol, and timolol. CGRP-based medications did not yet exist. The new document effectively superimposes modern migraine-specific therapy on top of the accumulated experience of traditional prevention.

Main traditional options

Drug/group	Initial purpose	Place in migraine prevention
Topiramate	Epilepsy	A well-proven preventative option
Propranolol	Cardiovascular diseases	One of the classic options for episodic migraine
Metoprolol	Cardiovascular diseases	Proven preventative effectiveness
Amitriptyline	Depression/pain syndromes	Can be used in selected patients
Venlafaxine	Depression/anxiety disorders	A possible preventative option
OnabotulinumtoxinA	Neuromuscular blockade	Effective for chronic migraine
Valproate/divalproex	Epilepsy	Effective, but the choice significantly limits the safety profile

There is still no "best migraine drug" for all patients.

Despite the large number of options, the recommendations do not create a simple table in which drug #1 should be prescribed to everyone, and #2 only after its failure. The authors suggest considering that for one person, the highest probability of reducing the number of attacks is more important, for another, the minimum number of side effects, and for a third, the absence of the need to remember to take a pill every day.

Comorbidities are also important. For example, a preventative medication that is effective for another existing condition can potentially avoid unnecessary medication burden. The new guideline includes specific recommendations and considerations for people with a high body mass index, fibromyalgia, hypertension, and pregnancy-related conditions.

The form of administration is equally important. Someone who finds it difficult to take pills daily may potentially have better compliance with a monthly medication. Another patient might categorically avoid injections and prefer an oral option even if they must take it daily. Poor adherence can render a theoretically effective medication practically useless, so treatment convenience becomes a significant clinical factor.

Finally, there's the financial aspect. New monoclonal antibodies and other migraine-specific medications are often significantly more expensive than older generics. Guidelines explicitly require cost discussions. This doesn't mean the cheapest medication should automatically be prescribed first, but price, insurance coverage, and the likelihood of long-term use all play a role in determining the true effectiveness of treatment.

What is the doctor asked to consider when choosing

Factor	Why is it important?
Proven effectiveness	Possibility of reducing the frequency/severity of attacks
Tolerability	Determines the possibility of long-term treatment
Associated diseases	Sometimes one drug helps with two conditions at once
Body weight	Some products may decrease or increase it.
Blood pressure	May influence the choice of certain medications
Pregnancy/pregnancy plans	Significantly limit the range of drugs
Tablet or injection	Affects commitment
Frequency of administration	Daily, every other day, monthly, quarterly
Price	Particularly relevant for new drugs
Previous treatment experience	The failure of one class does not mean the ineffectiveness of another

Some points of the new guideline have already sparked discussion among experts.

One controversial example was candesartan, an angiotensin receptor blocker widely used to treat hypertension and also to prevent migraines. The previous 2012 recommendation classified it as "possibly effective." The new document found insufficient evidence to support a stronger recommendation, prompting criticism from some experts, who cited existing placebo-controlled studies, good tolerability, and the drug's low cost.

Another example is rimegepant. This is a modern CGRP-blocking drug approved in the US for the prevention of episodic migraine back in 2021. However, a new expert group ranked it lower than several other migraine-specific medications in terms of evidence strength and recommends considering medications with a more robust evidence base for episodic migraine.

This decision is interesting to compare with the American Headache Society's 2024 position, which states that CGRP-targeted drugs, including rimegepant and atogepant, can be considered first-line options without requiring prior failure of existing therapies. The contradiction is only apparent: the position paper evaluated the class as a whole and clinical experience, whereas the new guideline ranks individual drugs according to a more formalized evidence system.

There's also a broader debate about how complex a clinical guideline should be. Independent experts have noted that a large number of subgroups and levels of evidence makes the document more personalized, but can also hinder its use in primary care. This is especially important because most people with migraine are seen not in specialized headache centers, but by family doctors and general practitioners.

Where the discussions remain

Question	Why there is no simple answer
CGRP drugs immediately or after old drugs?	Different guidelines use different criteria for evidence and cost.
Candesartan	It is used in practice, but a new assessment of the evidence has been restrained
Rimegepant	Regulatory approval, but given a lower evidence position in the 2026 guideline
Old cheap drugs versus new ones	Cost, portability and effectiveness need to be compared.
Too much personalization	Useful for specialists, but complicates the algorithm for primary care

Special care is required during pregnancy and planning of pregnancy.

Migraine is especially common among women of reproductive age, so the choice of preventive therapy cannot be considered without considering pregnancy and contraception. The new guideline includes specific recommendations for this situation, as medications that are perfectly acceptable for most adults may be undesirable or contraindicated during pregnancy.

The most illustrative example is topiramate. It has convincing prophylactic efficacy and, in some cases, may be attractive to overweight patients, as it can promote weight loss. However, the drug can cause harm to the fetus; the current official labeling warns of an increased risk of major birth defects, including cleft lip and/or palate, as well as small-for-gestational-age infants.

This clearly demonstrates why drug rankings cannot be based solely on their ability to reduce the number of migraine days. What is an advantage for one patient may be a serious disadvantage for another. For women who are capable of becoming pregnant, the physician should carefully consider their reproductive plans, contraceptive methods, and the potential impact of the drug on pregnancy before starting prophylactic therapy, not afterward.

The new recommendation also drew attention to potential differences between neurological and obstetric guidelines. This is particularly important because evidence for drug safety in pregnancy is almost always weaker than evidence for efficacy in non-pregnant adults: pregnant women are typically not included in standard clinical trials. Therefore, in real-world practice, decisions require an individualized risk-benefit assessment and, if necessary, the joint participation of a neurologist and obstetrician/gynecologist.

Why reproductive status matters when choosing

Factor	Practical significance
Planning a pregnancy	Should be considered before prescribing prophylaxis
Pregnancy that has already occurred	The range of acceptable means changes significantly
Topiramate	Has a proven risk to the fetus
Valproate	Also requires special care due to reproductive risks
New drugs	For some, there is less data on long-term use in pregnancy.
Solution	Individual risk-benefit balancing

Prevention is especially important when using seizure medications frequently.

The more frequent the attacks, the more likely a person is to regularly take painkillers, triptans, or other acute medications. When used too frequently, some of these medications can lead to medication overuse headaches. As a result, the treatment that initially helped control occasional attacks becomes part of the mechanism that maintains the high frequency of headaches.

This is one of the reasons why modern strategies aren't limited to searching for increasingly stronger medications for each attack. If a person is forced to constantly manage pain, another question must be asked: is it possible to reduce the number of days when the need for a life-saving medication arises? Prevention allows us to address precisely this aspect of the problem.

The new guideline specifically addresses patients who frequently use acute medications. According to the authors' analysis, modern CGRP-targeted drugs may remain effective in this group. In some patients, headache frequency decreases even as the overuse of medications for relieving attacks is reduced.

This doesn't mean that every patient should abruptly discontinue painkillers or triptans on their own. The strategy depends on which medications are used, how often, whether chronic migraine is present, and the severity of the headache's medication dependence. But the basic principle of the new recommendation is clear: frequent need for acute treatment is an argument in favor of assessing the need for preventive treatment, not a reason to endlessly increase the number of pills prescribed for an attack.

Acute therapy and prevention solve different problems

Acute therapy	Preventive therapy
Taken during an attack	Taken regularly
The goal is to stop the symptoms quickly.	The goal is to reduce future frequency and severity
May be required several times a month	Works for weeks and months
Excessive use of certain medications can cause problems	May reduce the need for acute therapy
Does not prevent the next attack by itself	This is exactly what prevention is aimed at.

It is recommended to check the result after 8-12 weeks, and not after a few pills.

Prophylactic medications also differ from acute treatments in how quickly the effect is assessed. While a triptan or other acute medication can be assessed within a few hours, prophylactic treatment often requires several weeks. The new recommendation suggests that physicians monitor the effectiveness of prescribed prophylaxis after approximately 8-12 weeks, depending on the specific medication.

For this purpose, it's useful to track not only the intensity of individual attacks, but especially the number of migraine and headache days per month. Therefore, a headache diary remains one of the most practical tools: it allows one to compare, for example, eight migraine days before treatment with four or five after several months of therapy, rather than relying solely on subjective recall.

However, effectiveness doesn't necessarily mean the disappearance of migraines. For a patient with ten severe headache days, reducing them to five can radically improve their ability to work and live a normal life. For another person, it's especially important that attacks become shorter, more easily controlled with an acute medication, or no longer require missed work. Therefore, the authors emphasize the importance of quality of life and functional outcomes, rather than a single laboratory or quantitative goal.

If treatment is ineffective or poorly tolerated, this does not mean that prophylaxis "does not work." The mechanisms of action of different agents vary significantly. As the guideline authors note, the ineffectiveness of one class does not predict the ineffectiveness of another. The expansion of the range of options was one of the main reasons for the need to update the document after a 14-year hiatus.

What to evaluate after starting prevention

Indicator	Why is it important?
Migraine days per month	One of the key performance indicators
All days of headaches	Especially important for chronic migraines
Severity of attacks	It may decrease even without completely disappearing.
Duration	The reduction of the attack is also clinically significant
Need for acute therapy	May decrease
Missed work/school days	Show functional effect
Adverse reactions	Determine tolerance
Quality of life	One of the main criteria of real benefit
First scheduled assessment	In about 8-12 weeks

Why did the update take almost eight years?

Work on the new document began back in January 2018. During preparation, several developments significantly complicated the task: new drugs entered the market, new clinical trials emerged, and some medications received additional indications. As a result, experts had to constantly consider the expanding evidence base.

The previous 2012 guideline was based primarily on studies conducted before 2009. Back then, the authors reviewed 284 publications during the initial screening stage, and the final analysis included 29 studies of high or moderately high evidence. While extremely useful for its time, it failed to take into account CGRP therapy, modern gepants, and the vast volume of subsequent chronic migraine research.

A large group of headache specialists and researchers from the United States and Canada participated in the development of the new document. About a third of the participants had potentially relevant conflicts of interest. According to the process description, these participants were not required to evaluate the relevant evidence base, and the development was led by authors without relevant conflicts. The American Academy of Neurology funded the draft guidelines.

This is important because the migraine prevention market is rapidly growing and includes expensive, patented medications. Expert advice can influence not only physician prescriptions but also insurance company reimbursement decisions. On the one hand, a strong evidence-based recommendation can facilitate patient access to a modern medication. On the other hand, overly strict ranking of medications can potentially be used by insurers to require patients to first undergo several less expensive treatment steps. This is precisely the issue being discussed by independent experts following the publication of the guideline.

How the evidence base has changed since 2012

2012	2026
The main focus is on episodic migraine	Episodic and chronic
There are no CGRP drugs yet.	A large class of migraine-specific drugs
Limited choice of biological methods	Monoclonal antibodies have gained a large evidence base
Mainly daily medications	Pills + monthly/quarterly options
Less data on special groups	Special attention to concomitant diseases
There is no clear new threshold for widespread prophylaxis	≥4 migraine days/month
2012 Update	New version after 14 years

What do the new guidelines actually change for patients?

The most practical change is that prevention is being discussed earlier than many people might otherwise consider necessary. A person doesn't have to have chronic daily headaches to be a candidate. Four significant migraine days per month are enough for a doctor to suggest such a discussion, and in cases of significant disability, prevention may be justified even with a lower frequency.

The second change is that choice has become significantly broader. Patients are no longer necessarily limited to trying several medications developed for epilepsy, hypertension, or depression. Migraine-specific options targeting CGRP have emerged, and the American Headache Society already considers this class a first-line option, without necessarily requiring the failure of two older classes of medications.

But a wider choice also makes the decision more complex. A new drug isn't necessarily better for a particular patient, and a high price or limited long-term data may outweigh a slight difference in efficacy. Conversely, for another patient, long-term poor tolerability of traditional drugs may make modern CGRP therapy a significantly more reasonable first choice. Therefore, the authors make shared decision-making between the patient and physician a central part of the guideline.

Finally, the update changes the understanding of treatment goals. Success doesn't necessarily mean "never having a migraine again." Realistic prevention should reduce the number and severity of attacks, decrease the need for acute medications, and restore days that the disease previously took away from work, family, and social life. This is why the number of migraine days is now considered alongside functional outcomes and quality of life.

Practical conclusions

Question	Response to the new guideline
Do you need to wait for 15 head days per month?	No
Are 4 migraine days enough?	Yes, prevention should be brought up for discussion.
What if there are fewer attacks, but they are very severe?	Prevention may also be justified
Is there one best medicine?	No
Is it necessary to start only with old drugs?	There is no single universal sequence for everyone
Are CGRP drugs considered?	Yes, this is one of the major updates.
Are topiramate and propranolol still relevant?	Yes
Is botulinum toxin used?	Yes, especially for chronic migraine
When to test the effect of a new preventative measure?	Usually in 8-12 weeks
Is it possible to choose a drug from the table on your own?	No, the choice depends on contraindications and individual risk profile.

Key points of the new recommendation

Position	Meaning
Migraine is a chronic neurological disease.	It should not be considered as just isolated attacks of pain.
Prevention is recommended for those with ≥4 migraine days per month.	The threshold is quite low
The functional impairment itself is significant	The number of attacks is not the only criterion
Chronic and episodic forms are considered.	The new guideline has become significantly wider
CGRP has become a major therapeutic target.	Special drugs against the migraine mechanism have appeared.
Traditional drugs remain relevant	Long experience and lower cost matter
Failure of one drug does not mean failure of all prevention	There are many mechanisms of action
Treatment should be personalized	Consider comorbidities, safety, cost, and preferences
The effect is not assessed immediately	Usually in 8-12 weeks
Target	Fewer migraine days, less severity and better daily function

News source

The primary scientific source is a new joint practice recommendation from the American Academy of Neurology and the American Headache Society:

Potrebic S. et al. Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations. Neurology. 2026. The paper was published on August 31, 2026, and is the first major update of the AAN/AHS guidelines since 2012. DOI: 10.1212/WNL.0000000000214881.

The document was also published in Headache, the official journal of the American Headache Society, and endorsed by the American Academy of Family Physicians. Funding for the development of the guideline was provided by the American Academy of Neurology.